Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response - Wu, Jenn-Yu; Wu, Shang-Gin; Yang, Chih-Hsin; Gow, Chien-Hung; Chang, Yih-Leong; Yu, Chong-Jen; Shih, Jin-Yuan; Yang, Pan-Chyr (Clinical cancer research, 2008)
Keywords: Aged; Aged, 80 and over; Antineoplastic agents; Antineoplastic Agents - pharmacology; Biological and medical sciences; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Drug Resistance, Neoplasm; EGFR; Exon 20; Exons; Female; Gefitinib; Humans; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Male; Medical sciences; Middle Aged; Mutation; Mutations; Pharmacology. Drug treatments; Pneumology; Quinazolines - pharmacology; Receptor, Epidermal Growth Factor - genetics; Treatment Outcome; Tumors of the respiratory system and mediastinum; Antineoplastic agent; Lung disease; Enzyme; Tyrosine kinase inhibitor; Respiratory disease; Quinazoline derivatives; Transferases; Lung cancer; Treatment efficiency; Enzyme inhibitor; Malignant tumor; Bronchopulmonary; Epidermal growth factor receptor; Growth factor receptor; Exon; Bronchus disease; Genetics; Mutation; Gefitinib; Protein-tyrosine kinase; Cancer